

Company registration number: 06924621

2B Scientific Limited

Unaudited financial statements

31 March 2017



2B Scientific Limited

Contents

	Page
Directors and other information	2
Statement of financial position	3 - 4
Statement of changes in equity	5
Notes to the financial statements	6 - 11

2B Scientific Limited

Directors and other information

Directors	T M Bernard J E Bernard
Company number	06924621
Registered office	Sanders Gate Churchfields Stonesfield Oxfordshire OX29 8PP
Business address	Cherwell Innovation Centre 77, Heyford Park Upper Heyford Oxfordshire OX25 5HD
Accountants	Plumridge Accountancy Limited Sanders Gate Churchfields Stonesfield Oxfordshire OX29 8PP

2B Scientific Limited

**Statement of financial position
31 March 2017**

	Note	2017 £	£	2016 £	£
Fixed assets					
Intangible assets	5	9,350		11,389	
Tangible assets	6	10,701		10,911	
			20,051		22,300
Current assets					
Stocks		61,547		34,422	
Debtors	7	290,789		199,669	
Cash at bank and in hand		55,642		55,246	
		407,978		289,337	
Creditors: amounts falling due within one year	8	(342,026)		(274,429)	
Net current assets			65,952		14,908
Total assets less current liabilities			86,003		37,208
Net assets			86,003		37,208
Capital and reserves					
Called up share capital			100		100
Profit and loss account			85,903		37,108
Shareholders funds			86,003		37,208

For the year ending 31 March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The shareholders have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.


In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

The notes on pages 6 to 11 form part of these financial statements.

2B Scientific Limited

Statement of financial position (continued)
31 March 2017

These financial statements were approved by the board of directors and authorised for issue on 27 September 2017, and are signed on behalf of the board by:



J E Bernard
Director

Company registration number: 06924621

The notes on pages 6 to 11 form part of these financial statements.

2B Scientific Limited

**Statement of changes in equity
Year ended 31 March 2017**

	Called up share capital £	Profit and loss account £	Total £
At 1 April 2015	100	53,920	54,020
Profit for the year		78,188	78,188
Total comprehensive income for the year	-	78,188	78,188
Dividends paid and payable		(95,000)	(95,000)
Total investments by and distributions to owners	-	(95,000)	(95,000)
At 31 March 2016 and 1 April 2016	100	37,108	37,208
Profit for the year		69,805	69,805
Total comprehensive income for the year	-	69,805	69,805
Dividends paid and payable		(21,010)	(21,010)
Total investments by and distributions to owners	-	(21,010)	(21,010)
At 31 March 2017	100	85,903	86,003

2B Scientific Limited

Notes to the financial statements Year ended 31 March 2017

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Sanders Gate, Churchfields, Stonesfield, Oxfordshire, OX29 8PP.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Transition to FRS 102

The entity transitioned from previous UK GAAP to FRS 102 as at 1 April 2015. Details of how FRS 102 has affected the reported financial position and financial performance is given in note 10.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Intangible assets

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses.

Intangible assets acquired as part of a business combination are recorded at the fair value at the acquisition date.

2B Scientific Limited

Notes to the financial statements (continued) Year ended 31 March 2017

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Website Development - 33% straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment - 25% reducing balance

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

2B Scientific Limited

Notes to the financial statements (continued) Year ended 31 March 2017

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

4. Profit before taxation

Profit before taxation is stated after charging/(crediting):

	2017	2016
	£	£
Amortisation of intangible assets	7,779	8,883
Depreciation of tangible assets	2,755	2,677

2B Scientific Limited

Notes to the financial statements (continued)
Year ended 31 March 2017

5. Intangible assets

	Other intangible assets £	Total £
Cost		
At 1 April 2016	30,400	30,400
Additions	5,740	5,740
At 31 March 2017	36,140	36,140
Amortisation		
At 1 April 2016	19,011	19,011
Charge for the year	7,779	7,779
At 31 March 2017	26,790	26,790
Carrying amount		
At 31 March 2017	9,350	9,350
At 31 March 2016	11,389	11,389

6. Tangible assets

	Fixtures, fittings and equipment £	Total £
Cost		
At 1 April 2016	16,675	16,675
Additions	3,818	3,818
Disposals	(2,598)	(2,598)
At 31 March 2017	17,895	17,895
Depreciation		
At 1 April 2016	5,764	5,764
Charge for the year	2,755	2,755
Disposals	(1,325)	(1,325)
At 31 March 2017	7,194	7,194
Carrying amount		
At 31 March 2017	10,701	10,701
At 31 March 2016	10,911	10,911

2B Scientific Limited

Notes to the financial statements (continued)
Year ended 31 March 2017

7. Debtors

	2017	2016
	£	£
Trade debtors	209,826	182,042
Other debtors	80,963	17,627
	<u>290,789</u>	<u>199,669</u>

8. Creditors: amounts falling due within one year

	2017	2016
	£	£
Trade creditors	286,228	185,887
Corporation tax	19,078	19,978
Social security and other taxes	5,637	4,003
Other creditors	31,083	64,561
	<u>342,026</u>	<u>274,429</u>

9. Directors advances, credits and guarantees

During the year the directors entered into the following advances and credits with the company:

2017

	Balance brought forward	Advances /(credits) to the directors	Balance o/standing
	£	£	£
T M Bernard	(25,000)	25,000	-
J E Bernard	(25,000)	25,000	-
	<u>(50,000)</u>	<u>50,000</u>	<u>-</u>

2016

	Balance brought forward	Advances /(credits) to the directors	Balance o/standing
	£	£	£
T M Bernard	(19,950)	(5,050)	(25,000)
J E Bernard	(19,950)	(5,050)	(25,000)
	<u>(39,900)</u>	<u>(10,100)</u>	<u>(50,000)</u>

2B Scientific Limited

Notes to the financial statements (continued)
Year ended 31 March 2017

10. Transition to FRS 102

These are the first financial statements that comply with FRS 102. The company transitioned to FRS 102 on 1 April 2015.

Reconciliation of equity

No transitional adjustments were required.

Reconciliation of profit or loss for the year

No transitional adjustments were required.